Millard Jessica L, Moraney Robyn, Childs Jordan C, Ewing Joseph A, Carbonell Alfredo M, Cobb William S, Warren Jeremy A
Department of Surgery, Prisma Health Upstate-Greenville Memorial, Greenville, SC, USA.
University of South Carolina School of Medicine-Greenville, Greenville, SC, USA.
Am Surg. 2020 Aug;86(8):965-970. doi: 10.1177/0003134820942179. Epub 2020 Aug 11.
Recent data on opioid consumption indicate that patients typically require far less than is prescribed. Prisma Health Upstate Hernia Center adopted standardized postoperative prescribing after hernia repair and began tracking patient-reported opioid utilization. The aim of this study is to evaluate patient opioid use after hernia repair in order to guide future prescribing.
All patients who underwent primary ventral (umbilical and epigastric), incisional, and inguinal hernia repair between February and May 2019 were reviewed. Patients reported the number of opioid pills taken at their first postoperative visit and documented either in the progress note or in the Americas Hernia Society Quality Collaborative (AHSQC) patient-reported outcomes (PRO) questionnaire. All demographic, operative, and outcomes data were captured prospectively in the AHSQC. Opioid use reported as milligram morphine equivalents (MME).
A total of 162 surgeries were performed during the study period, and 107 had patient-reported opioid use for analysis. Inguinal hernia repair was performed in 36 patients, 10 primary ventral hernia repairs, and 61 incisional hernia repairs. No opioid use was reported in 63.9% of inguinal hernias, 60% of primary ventral hernias, and 20% of incisional hernias. Inguinal hernia patients consumed a mean of 10.5 MME, primary ventral patients 11 MME, and incisional hernia patients 78.5 MME.
Patients require little to no opioid after primary ventral or inguinal hernia repair and opioid-free surgery is feasible. Incisional hernia is more heterogenous, but the majority of patients still required less opioid than previously thought.
近期有关阿片类药物使用的数据表明,患者通常所需的药物剂量远低于所开处方。普瑞isma健康上州疝气中心在疝气修补术后采用了标准化的术后处方,并开始跟踪患者报告的阿片类药物使用情况。本研究的目的是评估疝气修补术后患者的阿片类药物使用情况,以指导未来的处方开具。
回顾了2019年2月至5月期间所有接受原发性腹侧(脐部和上腹部)、切口疝和腹股沟疝修补术的患者。患者报告了术后首次就诊时服用的阿片类药物丸数,并记录在病程记录或美国疝气协会质量协作组织(AHSQC)患者报告结局(PRO)问卷中。所有人口统计学、手术和结局数据均前瞻性地记录在AHSQC中。阿片类药物使用量以毫克吗啡当量(MME)报告。
研究期间共进行了162例手术,其中107例有患者报告的阿片类药物使用情况可供分析。36例患者进行了腹股沟疝修补术,10例进行了原发性腹侧疝修补术,61例进行了切口疝修补术。63.9%的腹股沟疝、60%的原发性腹侧疝和20%的切口疝患者未报告使用阿片类药物。腹股沟疝患者平均服用10.5 MME,原发性腹侧疝患者服用11 MME,切口疝患者服用78.5 MME。
原发性腹侧或腹股沟疝修补术后患者很少或无需使用阿片类药物,无阿片类药物手术是可行的。切口疝情况更为复杂,但大多数患者所需的阿片类药物仍比之前认为的要少。